AI assistant
Sending…
NovaBay Pharmaceuticals, Inc. — Director's Dealing 2021
Dec 7, 2021
35098_dirs_2021-12-07_952d49f3-51cb-4d70-afa8-e4f82cf94a2f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: NovaBay Pharmaceuticals, Inc. (NBY)
CIK: 0001389545
Period of Report: 2021-12-03
Reporting Person: Kunin Audrey (Chief Product Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-12-03 | Common Stock | P | 101650 | $0.4625 | Acquired | 500000 | Indirect |
Footnotes
F1: This transaction was executed in multiple trades at prices ranging from $0.4600 to $0.4650. The price reported above reflected the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2: By The Audrey G. Kunin Trust in which the reporting person serves as the trustee and has investment control.
More from NovaBay Pharmaceuticals, Inc.
Earnings Release
2026
May 20
Interim / Quarterly Report
2026
May 15
Annual Report
2026
Apr 29
Regulatory Filings
2026
Apr 6
Board/Management Information
2026
Apr 1
Regulatory Filings
2026
Mar 23
Annual Report
2026
Mar 19
Share Issue/Capital Change
2026
Feb 20
Capital/Financing Update
2026
Feb 12
Proxy Solicitation & Information Statement
2026
Feb 10